Companies with late-stage RNA and oligonucleotide drugs
19 companies hold rights to 20 RNA and oligonucleotide drugs (siRNA, antisense, mRNA and other oligonucleotide drugs) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.
| Company | Ticker | Late-stage | Drugs (stage, indications) |
|---|---|---|---|
| Ionis Pharmaceuticals | IONS | 6 | Elsunersen (Phase 3, Epilepsy); Obudanersen (Phase 3, Angelman Syndrome); Pelacarsen (Phase 3, Atherosclerotic Cardiovascular Disease); Sefaxersen (Phase 3, IgA Nephropathy); Ulefnersen (Phase 3, Amyotrophic Lateral Sclerosis); Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia) |
| Alnylam Pharmaceuticals | ALNY | 4 | ALN-CIDEB (Phase 3, MASH / NASH); Cemdisiran (Phase 3, Age-Related Macular Degeneration, Myasthenia Gravis, Generalized Myasthenia Gravis); Nucresiran (Phase 3, Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy); Zilebesiran (Phase 3, Hypertension) |
| Novartis | NVS | 4 | Delpacibart braxlosiran (Phase 3, Facioscapulohumeral Muscular Dystrophy); Delpacibart etedesiran (Phase 3, Myotonic Dystrophy Type 1); NIO752 (Phase 3, Alzheimer's Disease, Progressive Supranuclear Palsy); Pelacarsen (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Arrowhead Pharmaceuticals | ARWR | 3 | Fazirsiran (Phase 3, Alpha-1 Antitrypsin Deficiency); Olpasiran (Phase 3, Atherosclerotic Cardiovascular Disease); Zodasiran (Phase 3, Homozygous Familial Hypercholesterolemia) |
| Regeneron Pharmaceuticals | REGN | 2 | ALN-CIDEB (Phase 3, MASH / NASH); Cemdisiran (Phase 3, Age-Related Macular Degeneration, Myasthenia Gravis, Generalized Myasthenia Gravis) |
| Roche | RHHBY | 2 | Sefaxersen (Phase 3, IgA Nephropathy); Zilebesiran (Phase 3, Hypertension) |
| Amgen | AMGN | 1 | Olpasiran (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Biogen | BIIB | 1 | Zorevunersen (Phase 3, Dravet Syndrome) |
| CSPC Pharmaceutical Group | 1093 | 1 | SYH2053 (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Dicerna Pharmaceuticals, Inc. | — | 1 | Lepodisiran (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Eli Lilly | LLY | 1 | Lepodisiran (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Otsuka Holdings | 4578 | 1 | Ulefnersen (Phase 3, Amyotrophic Lateral Sclerosis) |
| Praxis Precision Medicines, Inc. | PRAX | 1 | Elsunersen (Phase 3, Epilepsy) |
| PTC Therapeutics | PTCT | 1 | Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia) |
| Qilu Pharmaceutical | — | 1 | QLC7401 (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Stoke Therapeutics, Inc. | STOK | 1 | Zorevunersen (Phase 3, Dravet Syndrome) |
| Suzhou Ribo Life Science | 6938 | 1 | QLC7401 (Phase 3, Atherosclerotic Cardiovascular Disease) |
| Swedish Orphan Biovitrum AB (publ) | SOBI | 1 | Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia) |
| Takeda Pharmaceutical Company | TAK | 1 | Fazirsiran (Phase 3, Alpha-1 Antitrypsin Deficiency) |
Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.